Has Mohammad Mubbashar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,504 in general payments to Mohammad Mubbashar, MD across 57 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mohammad Mubbashar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mohammad Mubbashar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mohammad Mubbashar, MD

Child & Adolescent Psychiatry · Petersburg, VANPI 1619497823

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 28.6% of the total. Reporting peaked in 2024 at $835 and has fallen 58.3% since, to $348 in 2025.

$1,504in general payments, 2019–2025

Across 57 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Supernus Pharmaceuticals, Inc.$431
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$356
Lundbeck LLC$122
E.r. Squibb & Sons, L.L.C.$118
Teva Pharmaceuticals USA, Inc.$107
Axsome Therapeutics, Inc.$85
plus $285 from 7 others

What the payments were for

Food & beverage$1,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Supernus Pharmaceuticals, Inc.	3	$431
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	22	$356
Lundbeck LLC	7	$122
E.r. Squibb & Sons, L.L.C.	4	$118
Teva Pharmaceuticals USA, Inc.	6	$107
Axsome Therapeutics, Inc.	3	$85
Vanda Pharmaceuticals Inc.	2	$56
Corium, LLC	2	$51
Takeda Pharmaceuticals U.S.A., Inc.	2	$49
Alkermes, Inc.	2	$46
Johnson & Johnson	2	$41
Otsuka America Pharmaceutical, Inc.	1	$26
Neurocrine Biosciences, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

QELBREE$388
CAPLYTA$119

How this compares

$1,504 in reported general payments places this provider in the 75th percentile of 115 child & adolescent psychiatry providers in Virginia.

See all child & adolescent psychiatry providers in Virginia →

Medicare billing

Part B allowed, 2024

$67,941

Medicare patients

142

Services billed

920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Chlorpromazine Hcl	34	$6,210
Quetiapine Fumarate	42	$1,036
Divalproex Sodium	16	$1,033
Oxcarbazepine	22	$996
Trazodone Hcl	68	$886
Divalproex Sodium ErDivalproex Sodium	32	$884
Olanzapine	33	$765
Perphenazine	13	$744
Fluvoxamine Maleate	15	$689
Clozapine	14	$627
Olanzapine OdtOlanzapine	12	$581
Aripiprazole	23	$533
Haloperidol	24	$514
Lamotrigine	28	$488
Mirtazapine	38	$429

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Petersburg

Chandramouleswar AmaraPetersburg$10K
Haluk AydinPetersburg$2K
Thresa SimonPetersburg$2K
Devi VasuPetersburg$2K
James WooldridgePetersburg$449
Charles HallRichmond$10K
David GouldRichmond$9K
Rakesh ShahHopewell$7K
Vikas MangewalaFairfax$7K
Maria Carmen Rita Gonzales VigilarAshburn$6K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →